In recent years, peptides have emerged as significant assets in the fight against cancer, providing new possibilities in both therapeutic and diagnostic contexts. These short sequences of amino acids, consisting of 2 to 50 residues, have attracted considerable interest from researchers and healthcare professionals due to their high specificity, reduced toxicity relative to traditional chemotherapy, and adaptable characteristics. The approval of more than 30 peptide based medications for cancer treatment by regulatory bodies globally represents a noteworthy advancement in this area.
The effectiveness of peptides in cancer therapy can be linked to their distinctive attributes. Their compact structure promotes deeper tissue infiltration, while their strong selectivity enables precise delivery of therapeutic agents to cancerous cells, sparing healthy tissue. For example, goserelin, a peptide medication sanctioned for the treatment of breast and prostate cancer, operates by accurately targeting hormone receptors, effectively inhibiting tumor growth with minimal adverse effects. Likewise, octreotide, another approved peptide medication, has demonstrated significant efficacy in managing neuroendocrine tumors by selectively binding to somatostatin receptors that are overexpressed on cancer cells.
This new report provides the 2024 sales, market shares, and strategic profiles of major suppliers of Digital Mobile Radiography, Specimen Radiography, Mammography, Full Size C-Arm, Mini C-Arm, and Contrast Media.
The report includes a worldwide strategic overview of the diagnostic imaging market:
- 2024 estimates of the market size and growth.
- 2024-2029 sales forecasts by geographic region and modality.
- Review of the U.S. and international technological, regulatory, economic, demographic and social trends with potentially significant impact on the diagnostic imaging industry during the next five years.
- Analysis of major geographic regions, including North America, Europe, Japan and Latin America.
- Discussion of trends in X-ray, ultrasound, MRI, CT, nuclear medicine, PET, PACS and other technologies.
In the field of diagnostics, peptides have transformed cancer imaging and detection. Radiolabeled peptides, such as gallium-68 DOTATATE, have become essential tools in the identification and staging of neuroendocrine tumors through PET imaging. These peptide-based diagnostic methods provide greater sensitivity and specificity compared to traditional imaging techniques, facilitating earlier detection and more precise monitoring of disease progression.
The adaptability of peptides has facilitated their incorporation into a range of therapeutic approaches. Certain peptides specifically target cancer cells by interfering with critical cellular functions, while others serve as vehicles for delivering cytotoxic agents or radioactive materials. An illustrative example is the peptide drug conjugate Lutathera, which merges a somatostatin analog with a radioactive isotope to provide targeted radiation therapy to neuroendocrine tumor cells. Furthermore, peptide vaccines have demonstrated potential in activating the immune system to identify and combat cancer cells, marking a significant advancement in cancer immunotherapy.
Continuous progress in peptide engineering and delivery mechanisms is broadening the scope of these molecules. Researchers are innovating new methods to enhance peptide stability and bioavailability, including cyclization techniques and the use of non-standard amino acids. The advent of cell-penetrating peptides has created new avenues for the direct delivery of therapeutic agents into cancer cells. For example, RGD peptides have shown potential in targeting tumor blood vessels and enhancing drug delivery to solid tumors.
Tables
- 2024 Global Diagnostic Imaging Market
- Sales by Geographic Region and Country
- 2024 Global Diagnostic Imaging Market
- Sales Growth by Geographic Region and Country
- 2024 Global Diagnostic Imaging Market
- Sales by Modality and Business
- 2024 Global Diagnostic Imaging Market
- Sales by Modality/Business
- And Geographic Region
- 2024-2029 Global Diagnostic Imaging Market
- Sales Growth by Modality/Business
- 2024 US Digital Mobile Radiography Market
- Sales and Shares of Major Suppliers
- 2024 US Specimen Radiography Market
- Sales and Shares of Major Suppliers
- 2024 US Mammography Market
- Sales and Shares of Major Suppliers
- 2024 US Full Size C-Arm Market
- Sales and Shares of Major Suppliers
- 2024 US Mini C-Arm Market
- Sales and Shares of Major Suppliers
- 2024 US Contrast Media Market
- Sales and Shares of Major Suppliers
Table of Contents
1. Introduction to Peptide Therapeutics
1.1 Overview of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing and Functioning of Peptide Drugs
1.4 Significance of Peptides as Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy
2. Global Cancer Peptide Therapeutics Market Insight
2.1 Current Market Scenario
2.2 Future Market Opportunities
3. Cancer Peptide Research and Market Trends by Country
3.1 US
3.2 China
3.3 Japan
3.4 South Korea
3.5 Australia
3.6 India
3.7 Canada
3.8 EU
3.9 Latin America
3.10 Middle East
3.11 UK
4. Cancer Peptide Research and Market Trends by Indication
4.1 Breast Cancer
4.2 Hematological Malignancies
4.3 Urothelial Cancer
4.4 Prostate Cancer
4.5 Lung Cancer
4.6 Gastrointestinal Cancer
4.7 Gynecological Cancer
4.8 Skin Cancer
4.9 Pancreatic Cancer
4.10 CNS Cancers
5. Marketed Cancer Peptides Drugs and Generics Insight - Availability, Cost, Dosage, Indication and Patent Insight
5.1 Firmagon (Degarelix)
5.1 Eligard (Leuprolide)
5.2 Lupron (Leuprolide Acetate)
5.3 Gonax (Degarelix Acetate)
5.4 Trelstar (Triptorelin)
5.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
5.6 Velcade (Bortizomib)
5.7 Ninlaro (Ixazomib)
5.8 Kyprolis (Carfilzomib)
5.9 Istodax (Romidepsin)
5.10 Zoladex (Goserelin)
5.11 Cosmegen (Dactinomycin)
5.12 Somatuline Depot (Lanreotide)
5.13 Sandostatin (Octreotide Acetate)
5.14 Bynfezia Pen (Octreotide)
5.15 Lutathera (Lutetium Lu 177 dotatate)
5.16 Mepact (Mifamurtide)
5.17 Netspot (Gallium Ga 68 dotatate)
5.18 Camcevi (Leuprolide)
6. Marketed Cancer Peptides Drugs Sales Insight
6.1 Kyprolis
6.2 Zoladex
6.3 Lutathera
6.4 Sandostatin
6.5 Somatuline
6.6 Decapeptyl SR
6.7 Velcade
6.8 Ninlaro
6.9 Lupron
7. Global Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase II/III
7.7 Phase III
7.8 Preregistration
7.9 Registered
8. Marketed Peptide Cancer Drugs Clinical Insight By Company, Country and Indication
9. Global Peptide Cancer Drug Market Dynamics
9.1 Favorable Market Parameters
9.2 Commercialization Challenges
10. Therapeutic Peptide Targets
10.1 Signal Transduction Pathways
10.2 Cell Cycle Regulation
10.3 Cell Death Pathways
10.4 Tumor Suppressor Protein
10.5 Transcription Factors
11. Peptide Drugs v/s Conventional Cancer Therapeutics
11.1 Peptide v/s Chemotherapy
11.2 Peptide v/s Monoclonal Antibody
11.3 Peptide v/s Gene Therapy
11.4 Peptide v/s Immunotherapy
12. Different Approaches of Peptides in Cancer Therapeutics
12.1 Hormonal Peptides
12.2 Radionuclide Drug Carrier
12.3 Peptide Vaccines
12.4 Cytotoxic Drug Carrier
12.5 Anticancer Peptides
12.6 Other Anticancer Drugs Closely Related to Peptides
13. Neoantigen Vaccine: An Emerging Tumor Immunotherapy
13.1 Personalized Neoantigen Based Vaccine in Cancer
13.2 Clinical Progress and Future Prospects
14. Venom Peptides: New Era for Cancer Peptide Therapy
14.1 Relevance of Venom Based Peptide Therapeutics
14.2 Drug Development Trends and Future Growth Avenues of Venom Peptides
15. Competitive Landscape
15.1 3B Pharmaceuticals
15.2 AsclepiX Therapeutics
15.3 Bicycle Therapeutics
15.4 Biohaven Labs
15.5 BrightPath Biotherapeutics
15.6 Bristol-Myers Squibb
15.7 Edinburgh Molecular Imaging
15.8 Gnubiotics Sciences
15.9 IDP Pharma
15.10 Janux Therapeutics
15.11 Medikine
15.12 Modulation Therapeutics
15.13 Novartis
15.14 Parabilis Medicines
15.15 PeptiDream
15.16 Perspective Therapeutics
15.17 Pharm-Sintez
15.18 Roche
15.19 Sapience Therapeutics
15.20 Vigeo Therapeutics
List of Figures
Figure 1-1: Anticancer Peptides - Classification
Figure 1-2: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
Figure 1-3: Peptides - Significance as Cancer Therapeutics
Figure 1-4: US - Per Unit Cost of Cancer Drugs (US$)
Figure 1-5: Peptides - Role in Cancer Immunotherapy
Figure 2-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2023 - 2030
Figure 2-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2023 - 2030
Figure 3-1: 177Lu-EB-FAPI PRRT Phase 1 (NCT06081322) Study - Initiation and Completion Year
Figure 3-2: PeptiDream - Peptide Discovery Platform System (PDPS) Features
Figure 4-1: PVX-410 Phase 2 (NCT04634747) Study - Initiation and Completion Year
Figure 4-2: TH1902 Phase 1 (NCT04706962) Study - Initiation and Completion Year
Figure 4-3: Multi Peptide Vaccine Phase 1 (NCT06252584) Study - Initiation and Completion Year
Figure 4-4: SVN53-67/M57-KLH Phase 1 (NCT02334865) Study - Initiation and Completion Year
Figure 4-5: Zelenectide Pevedotin Phase 1 (NCT04561362) Study - Initiation and Completion Year
Figure 4-6: Zelenectide Pevedotin Phase 2/3 (NCT06225596) Study - Initiation and Completion Year
Figure 4-7: Alphalex Exatecan Phase 1/2 (NCT04902872) Study - Initiation and Completion Year
Figure 4-8: Personalized Cancer Vaccine Phase 1/2 (NCT06529822) Study - Initiation and Completion Year
Figure 4-9: PGV001 Based Personalized Multipeptide Vaccine Phase 1 (NCT05010200) Study - Initiation and Completion Year
Figure 4-10: TB511 Phase 1/2 (NCT06400160) Study - Initiation and Completion Year
Figure 4-11: MUC1 Peptide Poly-ICLC Vaccine Phase 1 (NCT03300817) Study - Initiation and Completion Year
Figure 4-12: UCPVax Phase 1/2 (NCT02818426) Study - Initiation and Completion Year
Figure 4-13: TH1902 Phase 1/2 (NCT04706962) Study - Initiation and Completion Year
Figure 4-14: ELI-002 7P Phase 1/2 (NCT05726864) Study - Initiation and Completion Year
Figure 4-15: Linaclotide Phase 2 (NCT03796884) Study - Initiation and Completion Year
Figure 4-16: CBX-12-201 Phase 2 (NCT06315491) Study - Initiation and Completion Year
Figure 4-17: UCPVax Phase 2 (NCT03946358) Study - Initiation and Completion Year
Figure 4-18: IO102-IO103 Phase 3 (NCT05155254) Study - Initiation and Completion Year
Figure 4-19: Dendritic Cell Vaccine Phase 1 (NCT03092453) Study - Initiation and Completion Year
Figure 4-20: LTX-315 - Mechanism of Action
Figure 4-21: LTX-315 Phase 2 (NCT06651151) Study - Initiation and Completion Year
Figure 4-22: LTX-315 Phase 2 (NCT04796194) Study - Initiation and Completion Year
Figure 4-23: Peptide Vaccine Phase 1 (NCT06564623) Study - Initiation and Completion Year
Figure 4-24: Motixafortide Phase 2 (NCT04543071) Study - Initiation and Completion Year
Figure 4-25: Personalized Neoantigen Vaccine Phase 1 (NCT03558945) Study - Initiation and Completion Year
Figure 4-26: SurVaxM Phase 2 (NCT05163080) Study - Initiation and Completion Year
Figure 4-27: SurVaxM Phase 2 (NCT02455557) Study - Initiation and Completion Year
Figure 4-28: SurVaxM Phase 1 (NCT04978727) Study - Initiation and Completion Year
Figure 4-29: ST101 Phase 2 (NCT04478279) Study - Initiation and Completion Year
Figure 4-30: Peptide VaCcine Phase 1 (NCT04808245) Study - Initiation and Completion Year
Figure 5-1: Firmagon - Patent Issue and Expiration Years
Figure 5-2: Firmagon - Price per Unit of 80 mg and 120 mg Powder for Subcutaneous Injection (US$), November’2024
Figure 5-3: Firmagon - Starting and Maintenance Dosage (mg)
Figure 5-4: Firmagon - Treatment Costs of Initial Cycle and Maintenance Cycle (US$), May’2023
Figure 5-5: Eligard - Cost of Different doses of Extended-Release Subcutaneous Powder for Injection (US$), November’2024
Figure 5-6: Eligard - Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
Figure 5-7: Eligard - Annual Treatment cost of Prostate Cancer using Different available Doses (US$), May’2023
Figure 5-8: Lupron - Patent Issue and Expiration Year for Sustained Release Preparation
Figure 5-9: Lupron - Price of Lupron Depot Intramuscular Kits by Dose (US$), November’2024
Figure 5-10: Lupron - Price of Lupron Depot Intramuscular Powder by Dose (US$), November’2024
Figure 5-11: Lupron - Average Annual Treatment Costs by Depot Type, November’2024
Figure 5-12: Gonax - Cost of Supply of Powder for Subcutaneous Injection (US$), November’2024
Figure 5-13: Gonax - Starting and Maintenance Dosage (mg)
Figure 5-14: Trelstar - Patent Issue and Expiration Year
Figure 5-15: Trelstar - Cost per Unit and Supply of Powder for Intramuscular Injection (US$), November’2024
Figure 5-16: Trelstar - Annual Treatment Cost by Dose (US$), November’2024
Figure 5-17: Decapeptyl SR - Price for a Supply of 3mg, 11.25mg and 22.5mg Powder for Injection (GBP/US$), November’2024
Figure 5-18: Decapeptyl SR - Recommended Dosage for Prostate Cancer (mg/week)
Figure 5-19: Decapeptyl SR - Annual Prostate Cancer Treatment Cost by Dose (US$), November’2024
Figure 5-20: Velcade - Price for a Supply of 3.5 mg Powder for Injection (US$), November’2024
Figure 5-21: Bortizomib - Price for Supply of Injectable Powder For Injection by Dose (US$), November’2024
Figure 5-22: Ninlaro - Patent Issue and Expiration Year
Figure 5-23: US - Price per Unit and Supply of Ninlaro Capsule (US$), November’2024
Figure 5-24: EU - Price of Supply of Ninlaro Capsule (EUR/US$), November’2024
Figure 5-25: Ninlaro - Recommended Dose and Dose Reductions for Treatment of Multiple Myeloma (mg/week)
Figure 5-26: Kyprolis - Issue and Expiration Year of Patents Assigned to Proteolix Inc
Figure 5-27: Kyprolis - Issue and Expiration Year of Patent Assigned to Cydex Pharmaceutical
Figure 5-28: Kyprolis - Issue and Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 5-29: Kyprolis - Price of 10mg, 30mg and 60mg Intravenous Powder for Injection (US$), November’2024
Figure 5-30: Kyprolis - Initial Dose and Maintenance Dose for Treatment of Multiple Myeloma (mg/m2/week)
Figure 5-31: Kyprolis - Initial Dose and Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 5-32: Romidepsin - FDA Approval Year by Indication
Figure 5-33: Istodax - Price for a Supply of Intravenous Powder (US$), November’2024
Figure 5-34: Romidepsin - Price per Unit and Supply by Dose Form (US$), November’2024
Figure 5-35: Zoladex - Cost of 3.6 mg and 10.8 mg Implant (US$), November’2024
Figure 5-36: Zoladex - Recommended Dose for Prostate cancer Management on Monthly Basis (mg/week)
Figure 5-37: Zoladex - Annual Treatment Cost using 3.6mg and 10.8mg Implant (US$), November’2024
Figure 5-38: Dactinomycin - Price for Generic and Branded 0.5 mg Powder for Injection (US$), November’2024
Figure 5-39: Somatuline Depot - Price per Unit and supply of Subcutaneous Solution by Dose (US$), November’2024
Figure 5-40: Lanreotide - Price per Unit and Supply of Subcutaneous Solution (US$), November’2024
Figure 5-41: Somatuline Depot - Treatment cost of 1 Cycle and Annual Treatment Cost of GEP-NETs and Carcinoid Syndrome (US$), November’2024
Figure 5-42: Sandostatin - Price per Unit and 10-Vial Supply by Dose (US$), November’2024
Figure 5-43: Sandostatin LAR - Price of Intramuscular Powder for Injection by Dose (US$), November’2024
Figure 5-44: Octreotide - Price per Unit and Supply of 10 mL Injectable Solution (US$), November’2024
Figure 5-45: Octreotide - Price per Unit and Supply of 5 mL Injectable Solution (US$), November’2024
Figure 5-46: Octreotide - Price per Unit and Supply of Intramuscular Powder for Injection by Dose (US$), November’2024
Figure 5-47: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor and Vasoactive Intestinal Peptide Tumor (mg/day)
Figure 5-48: Bynfezia Pen - Patent Issue and Expiration Year
Figure 5-49: Bynfezia Pen - Price per Unit and Supply of Subcutaneous Solution (US$), November’2024
Figure 5-50: Bynfezia Pen - Mean Dose for First 2 Week and Subsequent Weeks (mcg/day)
Figure 5-51: Lutathera - Patent Issue and Expiration Years
Figure 5-52: Lutathera - RDP and ODE Regional Expiry Years
Figure 5-53: Mepact - Recommended Number of Dose Administration/ Week for 12 and 24 Weeks Treatment
Figure 6-1: Kyprolis - Global Sales (US$ Million), 2020-2024
Figure 6-2: Kyprolis - Global Quarterly Sales Values (US$ Million), Q1-Q3’2024
Figure 6-3: Kyprolis - US Annual Sales (US$ Million), 2020-2024
Figure 6-4: Kyprolis - US Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-5: Kyprolis - ROW Annual Sales (US$ Million), 2020-2024
Figure 6-6: Kyprolis - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-7: Zoladex - Global Sales (US$ Million), 2020-2024
Figure 6-8: Zoladex - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-9: Zoladex - Global Sales By Region (US$ Million), 2024
Figure 6-10: Zoladex - Global Sales By Region (%), 2024
Figure 6-11: Zoladex - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-12: Zoladex - US Annual Sales (US$ Million), 2020-2024
Figure 6-13: Zoladex - US Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-14: Zoladex - Europe Annual Sales (US$ Million), 2020-2024
Figure 6-15: Zoladex - Europe Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-16: Zoladex - EM Annual Sales (US$ Million), 2020-2024
Figure 6-17: Zoladex - EM Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-18: Zoladex - ROW Annual Sales (US$ Million), 2020-2024
Figure 6-19: Zoladex - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-20: Lutathera - Global Sales (US$ Million), 2020-2024
Figure 6-21: Lutathera - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-22: Lutathera - Global Sales By Region (US$ Million), 2024
Figure 6-23: Lutathera - US Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-24: Lutathera - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-25: Sandostatin - Global Sales (US$ Million), 2020-2024
Figure 6-26: Sandostatin - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-27: Sandostatin - US Annual Sales (US$ Million), 2020-2024
Figure 6-28: Sandostatin - US Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-29: Sandostatin - ROW Annual Sales (US$ Million), 2020-2024
Figure 6-30: Sandostatin - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-31: Somatuline - Global Sales (US$ Million), 2020-2024
Figure 6-32: Somatuline - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-33: Somatuline - NA Sales (US$ Million), 2022-2024
Figure 6-34: Somatuline - NA Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-35: Somatuline - Europe Sales (US$ Million), 2022-2024
Figure 6-36: Somatuline - Europe Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-37: Somatuline - ROW Sales (US$ Million), 2022-2024
Figure 6-38: Somatuline - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-39: Decapeptyl - Global Sales (US$ Million), 2020-2024
Figure 6-40: Decapeptyl - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-41: Decapeptyl - Europe Sales (US$ Million), 2022-2024
Figure 6-42: Decapeptyl - Europe Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-43: Decapeptyl - ROW Sales (US$ Million), 2022-2024
Figure 6-44: Decapeptyl - ROW Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-45: Velcade - Global Sales (US$ Million), 2020-2024
Figure 6-46: Velcade - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 6-47: Ninlaro - Global Sales (US$ Million), 2020-2024
Figure 6-48: Ninlaro - Global Quarterly Sales (US$ Million), Q1-Q3’2024
Figure 6-49: Global - Lupron Annual Sales (US$ Million), 2019-2021
Figure 6-50: US - Lupron Annual Sales (US$ Million), 2019-2021
Figure 6-51: ROW - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2024 Till 2030
Figure 9-1: Global Peptide Cancer Drug Market - Favorable Parameters
Figure 9-2: Global Peptide Cancer Drug Market - Commercialization Challenges
Figure 10-1: Therapeutic Peptides Based on Their Biological Targets
Figure 10-2: MAPK Signaling Pathways
Figure 10-3: Cell Cycle in Eukaryotes
Figure 10-4: Cell Death Pathways
Figure 10-5: Features of Bcl-2 Family Proteins
Figure 11-1: Monoclonal Antibody - Limitations
Figure 11-2: Monoclonal Antibodies and Peptide Therapeutics - Cost of Production per gram (US$)
Figure 11-3: Pre-Requisite for Gene Therapy
Figure 11-4: Gene Therapy - Limitations
Figure 11-5: Immunotherapy - Drawbacks
Figure 12-1: Different Approaches of Peptide in Cancer Management
Figure 12-2: LHRH Agonist and LHRH Antagonist - Mode of Action
Figure 12-3: Somatostatin Analogs - Effects
Figure 12-4: Peptide Receptor Radionuclide Therapy
Figure 12-5: Peptide Vaccines - Mechanism
Figure 13-1: Neoantigen Vaccines - Benefits
Figure 13-2: Neoantigen Vaccine Production
Figure 13-3: Neoantigen Vaccine - Mode of Action
Figure 14-1: Venom Peptides - Advantages
List of Tables
Table 1-1: Source or Chemical Nature of Early Peptides
Table 5-1: Trelstar - Recommended Dose (mg/week)
Table 5-2: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma
Table 13-1: Neoantigen Vaccines in Clinical Trials
Table 14-1: Other Venom Peptides in Cancer Therapy
Companies Mentioned
- Bayer
- Becton Dickinson
- Beekley Medical
- Bracco
- Canon
- Carestream
- FujiFilm
- GE HealthCare
- Genoray Medical
- Guerbet
- Hologic
- Konica Minolta
- KUBTEC Medical
- Lantheus
- Mammotome/Danaher
- MinXray
- OrthoScan
- Philips
- Shimadzu
- Siemens Healthineers
- Turner Imaging
